Oct 28, 8:04am

I have the page's first half; the fetch cuts off mid-way through the antidepressants section. Let me map the rest of the page and verify recent developments in parallel.

The Wayback copy hits the same fetch cap, so I'll map the page's later sections via search snippets and verify recent developments in parallel.

Key regulatory facts confirmed. Now let me verify the remaining developments.

Nearly done verifying. A few final checks on the pipeline and policy items.

All facts are verified. Now I'll write up the memo as a canvas.

The Good Drug Guide — Suggested Updates (October 2026)

I've re-read the Guide and compiled a full editorial memo — it's open in the canvas (The Good Drug Guide — Suggested Updates), organised by page section with sources for every item. It builds on the update work you've already done on the page (JDTic, aticaprant, Exxua) rather than repeating it. Headline suggestions:

  1. Add the rapid-acting antidepressants — the biggest gap. Esketamine (Spravato, 2019, first new mechanism in decades), racemic ketamine clinics, Auvelity (2022, first oral rapid-acting) and zuranolone (2023, first oral postpartum-depression drug) transformed the post-SSRI landscape your antidepressant section describes (FDA, FDA).
  2. Psilocybin — no longer hypothetical: two positive Compass Phase 3 trials (June 2025, February 2026), six-month durability data, and an FDA rolling NDA review with a National Priority Voucher (Compass); Australia has authorised psychiatrist prescribing since 2023.
  3. MDMA section rewrite — the PTSD-therapy saga (Phase 3 success, August 2024 FDA rejection, resubmission in 2026), plus softening the flat "neurotoxic to serotonergic axons" claim and the rodent-derived Prozac-prophylaxis tip.
  4. Kappa-opioid antagonists: complete the trilogy — navacaprant failed Phase 3 in June 2026, after JDTic and aticaprant; the translational story is now three-for-three failure (MPR).
  5. GLP-1 agonists — semaglutide's alcohol-craving RCT and the whole "metabolic psychiatry" class are missing and directly on-theme (JAMA Psychiatry).
  6. Tobacco ending — "little hope of a more intelligent approach" is now obsolete: the Tobacco and Vapes Act 2026 (generational ban from 2027) and the disposable-vape ban (GOV.UK).
  7. Smaller fixes: oxytocin "trust in a bottle" failed high-powered replication; the THC/Alzheimer's amyloid claim has crumbled; GHB's "no discernible body-count" no longer holds in the UK; fentanyl/nitazene adulteration needs a caveat in the opioids passage; the Moncrieff serotonin review belongs in the "how do they really work?" discussion.

One caveat: my fetch of the page cut off partway through the antidepressants section, so the memo focuses on the introduction through the general antidepressant discussion — the SSRI-by-SSRI and "smart drugs" material wasn't fully readable. Happy to extend the memo to those sections, or draft replacement text for any passage.

Context on your wider update projects drawn from No access.

Oct 28, 8:04am

This is a shared conversation and may include unverified content that doesn't reflect Mistral AI's views. Login to resume chatting.

Vibe can make mistakes. Check answers. Learn more